OKUR.US OnKure Therapeutics, Inc.

Healthcare Biotechnology USA Stocks
2.80 USD
Close of Nov 17, 2026
2.01 5.38
Market cap
USD 113M
P/E
-
P/B
0.69x
ROE
-40.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is OKUR.US undervalued?

Graham number

The Graham number of OnKure Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

OnKure Therapeutics, Inc. fundamental analysis

No fundamental analysis for OnKure Therapeutics, Inc. yet.

OnKure Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and …

Full company profile